Table 3.
Associations of demographic, clinical, and treatment‐related variables with financial burden
| Any burden | Any financial burden | P‐value | ||
|---|---|---|---|---|
| N | % | OR (95% CI) | ||
| Age at LILAC participation [mean (SD)] | 76.6 | (5.4) | 0.93 (0.91, 0.94) | <0.001 |
| Age at diagnosis | ||||
| <65 | 138 | 9.4 | 1.00 | <0.001 |
| 65+ | 220 | 4.8 | 0.49 (0.39, 0.61) | |
| Race/ethnicity | ||||
| White | 306 | 5.6 | 1.00 | <0.001 |
| African‐American | 36 | 14.9 | 2.96 (2.04, 4.29) | |
| Other | 16 | 5.8 | 1.05 (0.62, 1.75) | |
| Educational attainment | ||||
| High school graduate or below | 43 | 4.9 | 1.00 | 0.16 |
| Some college | 136 | 6.9 | 1.44 (1.01, 2.04) | |
| College graduate | 96 | 5.6 | 1.15 (0.79, 1.66) | |
| Graduate or professional degree | 83 | 6.0 | 1.24 (0.85, 1.81) | |
| Household income at baseline | ||||
| <$20 000 | 45 | 10.2 | 1.00 | 0.003 |
| $20 000‐34 999 | 61 | 5.3 | 0.50 (0.33, 0.74) | |
| $35 000‐49 999 | 74 | 6.4 | 0.60 (0.41, 0.88) | |
| $50 000‐74 999 | 82 | 5.9 | 0.56 (0.37, 0.80) | |
| $75 000+ | 82 | 5.2 | 0.48 (0.33, 0.71) | |
| Social support | ||||
| Low (0‐65) | 118 | 6.9 | 1.00 | 0.076 |
| Medium (66‐85) | 91 | 5.6 | 0.81 (0.61, 1.07) | |
| High (86‐100) | 112 | 5.2 | 0.74 (0.57, 0.97) | |
| Insurance status at diagnosis | ||||
| Uninsured | 7 | 17.9 | 1.98 (0.81, 4.82) | <0.001 |
| Public only | 34 | 10.0 | 1.00 | |
| Private insurance | 101 | 7.4 | 0.72 (0.48, 1.08) | |
| Public/private combination | 163 | 4.7 | 0.44 (0.30, 0.65) | |
| VA with or without other insurance | 7 | 2.3 | 0.22 (0.09, 0.49) | |
| Cancer site/type | ||||
| Breast | 204 | 5.8 | 1.00 | 0.057 |
| Colorectal | 44 | 7.0 | 1.23 (0.87, 1.72) | |
| Endometrial | 33 | 6.2 | 1.08 (0.74, 1.57) | |
| Melanoma | 12 | 3.1 | 0.52 (0.29, 0.94) | |
| Non‐Hodgkin's lymphoma | 17 | 4.7 | 0.81 (0.49, 1.35) | |
| Lung | 20 | 7.0 | 1.22 (0.76, 1.97) | |
| Leukemia | 13 | 10.3 | 1.88 (1.04, 3.39) | |
| Ovarian | 11 | 9.0 | 1.62 (0.86, 3.05) | |
| Fallopian tube | 2 | 11.1 | 2.04 (0.47, 8.94) | |
| Peritoneum | 2 | 13.3 | 2.51 (0.56, 11.21) | |
| Time since diagnosis | ||||
| <5 y | 102 | 6.4 | 1.00 | 0.43 |
| 5+ y | 256 | 5.8 | 0.92 (0.72, 1.15) | |
| Stage at diagnosis | ||||
| Local | 215 | 5.0 | 1.00 | <0.001 |
| Regional | 101 | 8.2 | 1.69 (1.32, 2.15) | |
| Distant | 37 | 8.4 | 1.74 (1.21, 2.50) | |
| Treatment (vs none) | ||||
| Any chemotherapy | 160 | 8.9 | 1.97 (1.58, 2.44) | <0.001 |
| Any radiation | 180 | 6.3 | 1.12 (0.91, 1.39) | 0.28 |
| Any hormone therapy | 150 | 6.2 | 1.07 (0.86, 1.32) | 0.56 |
| Modified Charlson score | ||||
| 0 | 140 | 5.0 | 1.00 | 0.001 |
| 1 | 93 | 5.7 | 1.14 (0.87, 1.49) | |
| 2+ | 125 | 7.8 | 1.59 (1.24, 2.04) | |
CI, confidence interval; LILAC, Life and Longevity After Cancer; OR, odds ratio; SD, standard deviation; VA, United States Department of Veterans Affairs